en · de · es · pt
melanotan-2-notes.peptides3626.com › Data › Melanotan-2 Identity And Regulatory Status — Deep Dive

Melanotan-2 Identity And Regulatory Status — Deep Dive

By Editorial Desk · published 2025-08-20 · last reviewed 2025-10-06 · Data

melanotan-2 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Identity And Regulatory Status

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-melanocyte-stimulating hormone
Common synonymsMT-II; melanotan 2No internationally accepted non-proprietary name
Typical presentationLyophilised powder in a sealed vialOften supplied alongside a separate diluent
Regulatory statusUnapproved therapeutic substanceCustoms seizure reported in several jurisdictions
Reported route in useSubcutaneous injectionSelf-administered outside clinical settings

Peptide Identity and Structural Background

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Related pages on this site

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Further detail

=== Guatemala === The Mexican Army crackdown has driven some cartels to seek a safer location for their operations across the border in Guatemala, attracted by corruption, weak policing, and its position on the overland smuggling route. The smugglers pick up drugs from small planes that land at private airstrips hidden in the Guatemalan jungle. The cargo is then moved up through Mexico to the U.S. border. Guatemala has also arrested dozens of drug suspects and torched huge cannabis and poppy fields. The U.S. government sent speedboats and night-vision goggles under a regional drug aid package. Los Zetas have gained ground in Guatemala after they killed several high-profile members and the supreme leader of Los Leones, an organized crime group from Guatemala. In February 2009, Los Zetas threatened to kill the president of Guatemala, Álvaro Colom. On March 1, 2010, Guatemala's chief of national police and the country's top anti-drugs official were arrested over alleged links to drug trafficking. A report from the Brookings Institution warns that, without proactive, timely efforts, the violence will spread throughout the Central American region. In August 2025, Guatemala granted temporary humanitarian status to 161 Mexicans fleeing cartel violence in Chiapas.

=== Isolation === Before the isotopes can be separated and a ratio can be determined, the desired component of the tissue must be isolated. Such components include collagen, carbonate and apatite. Each component requires different means of isolation, and methods must be further specialised to account for the varied levels of decay and contamination which may occur as a result of taphonomy. In the case of collagen, there are three main modes of isolation:

== Adverse effects == Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain. Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.

Sources: en.wikipedia.org

Background from the literature

== Production == Nitrogen gas is an industrial gas produced by the fractional distillation of liquid air, or by mechanical means using gaseous air (pressurised reverse osmosis membrane or pressure swing adsorption). Nitrogen gas generators using membranes or pressure swing adsorption (PSA) are typically more cost and energy efficient than bulk-delivered nitrogen. Commercial nitrogen is often a byproduct of air-processing for industrial concentration of oxygen for steelmaking and other purposes. When supplied compressed in cylinders it is often called OFN (oxygen-free nitrogen). Commercial-grade nitrogen already contains at most 20 ppm oxygen, and specially purified grades containing at most 2 ppm oxygen and 10 ppm argon are also available. In a chemical laboratory, it is prepared by treating an aqueous solution of ammonium chloride with sodium nitrite.

In 2001, Otto Reich, a hardline Republican Anti-Castro Cuban-born exile in the United States, who had formerly been involved in the Iran–Contra affair, was at the time the Assistant Secretary of State for Western Hemisphere Affairs. He approached Marc Wachtenheim from the Pan American Development Foundation, a subcontractor for the United States Agency for International Development (USAID), to hatch a development program to reopen Cuba, and then developed a covert influence campaign that might lead to conditions that could foment revolution there. They decided that because Freemasonry had been so present in Cuban society, to cultivate the Grand Lodge of Cuba. In 2001, Marc Wachtenheim brought Grand Master Collera Venta to Washington, D.C. to meet with Otto Reich. The staff of the United States Interests Section in Havana were well aware of the fact that Grand Master Collera Venta was a Cuban counterintelligence officer at the State Security Unit (DSE) (Spanish: Departamento de Seguridad del Estado) who went by the codename Agente Gerardo, and had been a spy for over 25 years. They did not share this information with USAID, nor any of their subcontractors, because the subcontractors didn't share their own plans with the Interests Section. The greater staff of the US diplomatic mission in Havana were aware of Collera Venta's true employment by 2007 – but they still did not inform USAID. Collera Venta later told CNN: "My job was to discover and neutralize these plans against my country."

=== Portugal === In Portugal, a resident physician is one undergoing postgraduate training aimed at obtaining a medical specialty. This training period begins after completing medical school and can last between 5 and 7 years, depending on the chosen specialty. At the end of their residency, physicians attain the status of specialist. The Medical Residency in Portugal is regulated by Decree-Law No. 60/2007, of March 13, and by Ordinance No. 183/2006, of February 22 (Medical Residency Regulation). It is organized into two training periods: the Common Year and the Professional Specialization Area. Until 2004, the residency was divided into General (2 years) and Complementary (3 to 6 years) phases. Upon completing medical school, doctors apply to a national competition for admission into the Medical Residency. This competition determines their placement for training locations and specialties, prioritizing the score obtained in a national ranking exam (a test with one hundred questions and five multiple-choice answers). The second criterion, used only in cases of a tie, is the medical school final grade. There is frequent confusion between a resident physician and an internal medicine specialist, also known as an internist. These terms are not synonymous, even though a resident physician may be pursuing specialization in internal medicine. The Portuguese Medical Association is the entity that regulates medical practice in Portugal, ensuring the technical-scientific postgraduate training of its members through residency programs, which grant physicians specialist status.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II approved for medical use?

No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.

Where did melanotan II originate?

It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.

Why is purity a concern for unapproved peptides?

Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.

Is melanotan-2 a natural hormone?

No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.

Network